Clinical Trial

Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers

Completed Phase 1
View on ClinicalTrials.gov →
Summary
In order to improve the medication convenience and compliance of patients and facilitates in the long-term control of disease condition, it is planned to reduced the number of injections to one per administration. The study aims to compare the safety and pharmacokinetics data to assess feasibility of single-site and multiple-site injection for administration.
Protocol Amendment History 3 changes
critical Trial completed 2026-07-31
notable Primary completion pushed: 2025-06 -> 2025-11-01 2026-07-31
minor Completion pushed: 2025-07 -> 2025-11-01 2026-07-31
Trial Details
NCT Number NCT06837077
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Hypercholesterolemia and Hyperlipidemia
Enrollment 49 participants
Start Date 2025-03-14
Primary Completion 2025-11-01 (estimated)
Study Completion 2025-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-30